Ignite Creation Date:
2024-05-06 @ 4:04 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04868708
Status:
COMPLETED
Last Update Posted:
2024-04-25
First Post:
2021-04-05
Brief Title:
A Study of AK104 an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody in Recurrent or Metastatic Cervical Cancer
Sponsor:
Akeso
Organization:
Akeso
Study Overview
Official Title:
A Multicenter Open-label Phase II Study of AK104an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody in the Treatment of Recurrent or Metastatic Cervical Cancer
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open-label phase II clinical study conducted in China All subjects will receive AK104 in combination with standard treatment regimens or AK104 alone The primary end point is safety The secondary end point is efficacy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None